ASCO GU 2026: Updates in metastatic prostate cancer
Dr Güldane Cengiz Seval speaks to ecancer about her experience treating multiple myeloma in Turkey.
She begins by detailing the International Staging System (R2-ISS) and Mayo Additive Staging System (MASS) and how these are aiding treatment decision and patient management.
Dr Cengiz Seval then shares findings from a study that she presented on 'post-induction MRD' at IMS 2023.
She also discusses some of the issues facing multiple myeloma treatment in Turkey and gives her thoughts on possible solutions.
ASCO GU 2026: Updates in metastatic prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
Current state of cancer genomics in Africa
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Status of anti BCMA therapy in myeloma
Multiple myeloma In Rwanda: The need for further research
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus